U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...

Nxera Pharma Co., Ltd. announces that it has entered a license, supply and commercialization agreement with Holling Bio-Pharma Corp. (Holling) for daridorexant in Taiwan. Daridorexant is an oral dual ...

Dr. Makoto Sugita, CMO and President of Nxera Pharma Japan, commented: “This new partnership with Holling will enable us to bring daridorexant, a potential best-in-class treatment, to the growing ...

The agreement was signed concurrently with Nxera’s assignment of its option to these same rights from Idorsia Pharmaceuticals Ltd under its agreement in July 2023 to acquire Idorsia Pharmaceuticals ...

Dr. Makoto Sugita, CMO and President of Nxera Pharma Japan, commented: “This new partnership with Holling will enable us to bring daridorexant, a potential best-in-class treatment, to the ...

Nxera Pharma has sold the Asia-Pacific rights to Idorsia's phase 3-stage autoimmune drug to Viatris for $10 million upfront. The drug in question is cenerimod, a S1P1 receptor modulator currently ...